Navigation Links
Eprodisate in Medical News

Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational pr...

Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis

ECUBLENS, Switzerland, Dec. 14 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medi...

Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review

ECUBLENS, Switzerland, Dec. 6 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company has received an acknowledgement from the United States Food and Drug Administration (FDA) tha...

BELLUS Health reports results for first quarter of fiscal 2009

...revenue (non-monetary liability) to accrued liability (monetary liability) following the recovery by the Company of ownership rights in and control of eprodisate (KIACTA(TM)). Other income amounted to $529,000 for the current quarter, compared to $278,000 for the same quarter the previous year. Other incom...

BELLUS Health reports results for the fourth quarter of 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ision to continue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the US Food...

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update

...arily due to funds used in operating activities. eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis With respect to eprodisate (KIACTA(TM)), the Company submitted a proposed pro...II trial, should be sufficient to gain approval of eprodisate (KIACTA(TM)) for the treatment of AA Amyloidosis,....

BELLUS Health provides update on activities

...lic syndrome and Alzheimer's disease. The Company expects to file the Investigational New Drug application for the second Phase III clinical trial for eprodisate (KIACTA(TM)) for the treatment of Amyloid A amyloidosis in the fourth quarter of 2008. With respect to this second Phase III KIACTA(TM) clinical tri...

BELLUS HEALTH reports results for first quarter of fiscal 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ecision to pursue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Fo...

At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)

...also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of Johnson and ...ly announced, Neurochem will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administratio...

Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives

...n July 2007 for the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i... the marketing authorization application (MAA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i...ts of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns...
Eprodisate in Medical Technology

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. , announces that the New England Journal of Medicine (NEJM) published the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT), recognize...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

...t Neurochem Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by th...
Other Tags
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... of conventional in vitro fertilization (IVF) -- the incubation of ... in a device inside the vagina, new research suggests. ... device, called an INVOcell, might sharply cut costs for pricey ... technology more accessible to those who don,t live near big-city ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. 21, 2014 (HealthDay News) -- ... NBC News in Liberia has cleared the virus from ... Medical Center in Omaha, where he had been treated for the ... confirmed by the U.S. Centers for Disease Control and Prevention found ... NBC News reported Tuesday night. "Recovering from Ebola is ...
(Date:10/20/2014)... Allegheny General Hospital’s (AGH) Cardiovascular Institute is offering ... a damaged mitral valve as the heart continues to ... Abbott Vascular , is designed to treat degenerative ... which the heart’s mitral valve leaflets fail to close ... left ventricle into the left atrium. The heart must ...
(Date:10/20/2014)... 20, 2014 Women’s health specialist, Dr. ... & Gynecology of Columbus, Inc., A Division of MaternOhio ... to more than 100,000 patients annually. Dr. Murphy will ... and stages of a women’s life. She is accepting ... in Westerville and Dublin. , Dr. Murphy offers a ...
(Date:10/20/2014)... 20, 2014 Zereana Jess-Huff, a 34-year-old mother, ... 2014 on a platform to think outside the bra. She ... her position to raise awareness about women’s other lady parts. ... cancer. You say the color pink and everybody knows what ... a fact that it has not been won when it ...
Breaking Medicine News(10 mins):Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
(Date:10/17/2014)... of Copenhagen have shown for the first time how ... fibrosis patients, giving them the opportunity to get tremendous ... , The study also discovered the bacterial growth in ... halted or slowed down by the immune cells. The ... and helped "suffocate" the bacteria, forcing the bacteria to ...
(Date:10/16/2014)... how the bowel lining develops and, in the process, ... , The researchers produced evidence that stem cells are ... a feature of the bowel lining, and believe these ... controversial finding as scientists are still divided on the ... Chin Wee Tan and Professor Tony Burgess from the ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
Other Contents